Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 6367

1.

Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'

Buti M, Esteban R.

Expert Rev Gastroenterol Hepatol. 2014 Sep 15:1-11. [Epub ahead of print]

PMID:
25222289
[PubMed - as supplied by publisher]
2.

Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.

van der Ree MH, van der Meer AJ, de Bruijne J, Maan R, van Vliet A, Welzel TM, Zeuzem S, Lawitz EJ, Rodriguez-Torres M, Kupcova V, Wiercinska-Drapalo A, Hodges MR, Janssen HL, Reesink HW.

Antiviral Res. 2014 Sep 8. pii: S0166-3542(14)00252-6. doi: 10.1016/j.antiviral.2014.08.015. [Epub ahead of print]

PMID:
25218783
[PubMed - as supplied by publisher]
3.

CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients.

Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, Guzmán-Fulgencio M, Aldámiz-Echevarria T, Carrero A, García-Álvarez M, Diez C, Tejerina F, Briz V, Resino S.

J Clin Virol. 2014 Sep 1. pii: S1386-6532(14)00320-5. doi: 10.1016/j.jcv.2014.08.020. [Epub ahead of print]

PMID:
25218243
[PubMed - as supplied by publisher]
4.

Response-guided Boceprevir-based Triple-Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study.

Mattias M, Sebastian S, Philipp S, Payer BA, Aichelburg MC, Gerold L, Katharina GP, Michael T, Markus PR, Thomas R.

J Infect Dis. 2014 Sep 11. pii: jiu516. [Epub ahead of print]

PMID:
25214517
[PubMed - as supplied by publisher]
5.

Severe thrombocytopenia in a patient with hepatitis C treated with eltrombopag from off-label drug use to on-label drug use: a case report.

Al-Jafar HA, Al-Khaldi J, Alduaij A, Al-Banwan K.

J Med Case Rep. 2014 Sep 10;8(1):303. [Epub ahead of print]

PMID:
25209590
[PubMed - as supplied by publisher]
Free Article
6.

Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection.

Flanagan S, Crawford-Jones A, Orkin C.

Expert Rev Clin Pharmacol. 2014 Sep 11:1-14. [Epub ahead of print]

PMID:
25209158
[PubMed - as supplied by publisher]
7.

Daily Low-Dose Tacrolimus Is a Safe and Effective Immunosuppressive Regimen During Telaprevir-Based Triple Therapy for Hepatitis C Virus Recurrence After Liver Transplant.

Papadopoulos-Köhn A, Achterfeld A, Paul A, Canbay A, Timm J, Jochum C, Gerken G, Herzer K.

Transplantation. 2014 Sep 9. [Epub ahead of print]

PMID:
25208324
[PubMed - as supplied by publisher]
8.

Simeprevir for the treatment of hepatitis C virus infection.

Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E.

Pharmgenomics Pers Med. 2014 Aug 14;7:241-9. doi: 10.2147/PGPM.S52715. eCollection 2014. Review.

PMID:
25206310
[PubMed]
Free PMC Article
9.

Not so sweet: autoimmune diabetes mellitus on triple therapy for chronic hepatitis C infection.

Blanchard E, Vickers CR, Samaras K.

Diabet Med. 2014 Sep 10. doi: 10.1111/dme.12585. [Epub ahead of print]

PMID:
25204264
[PubMed - as supplied by publisher]
11.

[Cases of hepatitis C virus infection with 2i/2a recombination genotype in the Lanzhou area and effects of related genetic variations on interferon alpha response].

Zhang WJ, Du SC, Yang JJ, Qu Y, Mao WW, Li J, Li CX, Tian SJ, Gong YX, Rao HY, Kong WJ.

Zhonghua Gan Zang Bing Za Zhi. 2014 Jul;22(7):484-9. doi: 10.3760/cma.j.issn.1007-3418.2014.07.002. Chinese.

PMID:
25203797
[PubMed - in process]
12.

Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic HCV, genotype-1 infected patients.

Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S.

Hepatology. 2014 Sep 9. doi: 10.1002/hep.27424. [Epub ahead of print]

PMID:
25203718
[PubMed - as supplied by publisher]
13.

[Genomic diversity of the genotype 1b hepatitis C virus open reading frame is correlated with outcomes of combined pegylated-interferon/ribavirin therapy in patients with chronic hepatitis C from Henan Province].

Zeng YL, Kang Y, Shang J.

Zhonghua Gan Zang Bing Za Zhi. 2014 Jun;22(6):401-6. doi: 10.3760/cma.j.issn.1007-3418.2014.06.001. Chinese.

PMID:
25203700
[PubMed - in process]
14.

Predictive Potential of IL-18 -607 and Osteopontin -442 Polymorphism in Interferon-Based Therapy of HCV Infection in the Pakistani Population.

Imran M, Manzoor S, Parvaiz F.

Viral Immunol. 2014 Sep 8. [Epub ahead of print]

PMID:
25198668
[PubMed - as supplied by publisher]
15.

Successful antiviral triple therapy in a longstanding refractory hepatitis C virus infection with an acute kidney injury.

Callau Monje D, Braun N, Latus J, Amann K, Alscher MD, Kimmel M.

Case Rep Nephrol. 2014;2014:308729. doi: 10.1155/2014/308729. Epub 2014 Aug 14.

PMID:
25197586
[PubMed]
Free PMC Article
16.

Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients.

Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y.

Gastroenterol Res Pract. 2014;2014:549709. doi: 10.1155/2014/549709. Epub 2014 Aug 14.

PMID:
25197269
[PubMed]
Free PMC Article
17.

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.

Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, Umemura T, Takehara T, Sakamoto N, Nishigaki Y, Nakane K, Toda N, Ide T, Yanase M, Hino K, Gao B, Garrison KL, Dvory-Sobol H, Ishizaki A, Omote M, Brainard D, Knox S, Symonds WT, McHutchison JG, Yatsuhashi H, Mizokami M.

J Viral Hepat. 2014 Sep 8. doi: 10.1111/jvh.12312. [Epub ahead of print]

PMID:
25196837
[PubMed - as supplied by publisher]
18.

Efficacy of Telaprevir-based Therapy for Difficult-to-treat Patients with Genotype 2 Chronic Hepatitis C in Japan.

Kumada H, Sato K, Takehara T, Nakamuta M, Ishigami M, Chayama K, Toyota J, Suzuki F, Nakayasu Y, Ochi M, Yamada I, Okanoue T.

Hepatol Res. 2014 Sep 5. doi: 10.1111/hepr.12416. [Epub ahead of print]

PMID:
25196718
[PubMed - as supplied by publisher]
19.

What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?

McDonald SA, Innes HA, Hayes PC, Dillon JF, Mills PR, Goldberg DJ, Barclay S, Allen S, Fox R, Fraser A, Kennedy N, Bhattacharyya D, Hutchinson SJ.

J Hepatol. 2014 Sep 4. pii: S0168-8278(14)00635-7. doi: 10.1016/j.jhep.2014.08.046. [Epub ahead of print]

PMID:
25195556
[PubMed - as supplied by publisher]
20.

The intracellular inhibition of HCV replication represents a novel mechanism of action by the innate immune Lactoferrin protein.

Picard-Jean F, Bouchard S, Larivée G, Bisaillon M.

Antiviral Res. 2014 Sep 1;111C:13-22. doi: 10.1016/j.antiviral.2014.08.012. [Epub ahead of print]

PMID:
25193851
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk